The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Open accessAbstract
Imatinib mesylate treatment markedly reduces the burden of leukemia cells in chronic myelogenous leukemia (CML) patients. However, patients remain at risk for relapse on discontinuing treatment. We have previously shown that residual BCR-ABL+ progenitors can be detected in CML patients within the first 2 years of imatinib treatment. However, reduced rates of relapse and continued decline of BCR-ABL levels with prolonged treatment, together with the ability of selected patients to maintain remission after discontinuing treatment, led us to investigate whether prolonged imatinib exposure resulted in reduction or elimination of BCR-ABL+ stem cells. We evaluated BCR-ABL expression in CD34+CD38+ (38+) committed progenitors and CD34+CD38− (38−) stem/primitive progenitor cells in samples from CML patients on imatinib treatment for at least 4 years with cytogenetic and molecular response. High levels of BCR-ABL expression were maintained over time in the 38− stem cell fraction. The absolute frequency of BCR-ABL+ cells as determined by limiting dilution analysis was consistently higher in 38− compared with 38+ cells. Transplantation into NOD/SCID-IL2Rγ-chain knockout mice demonstrated that BCR-ABL+ cells had long-term in vivo repopulating capacity. These results directly demonstrate that BCR-ABL+ stem cells persist in CML patients despite prolonged treatment with imatinib, and support ongoing efforts to target this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Dynamics of chronic myeloid leukaemia
Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P., Sawyers, C. L., & Nowak, M. A. (2005) · Nature · doi:10.1038/nature03669 · Cited by 833
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell That Maintains Expression of CD4
Schnittman, S. M., Psallidopoulos, M. C., Lane, H. C., Thompson, L., Baseler, M., Massari, F., Fox, C. H., Salzman, N. P., & Fauci, A. S. (1989) · Science · doi:10.1126/science.2665081 · Cited by 714
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
“These data provide a proof-of-principle for the hypothesis that TKI treatment can be discontinued safely, even though someBCR-ABL11 cells always remain detectable.(130-132) However, the data are still insufficient to make recommendations about discontinuing treatment outside of well-designed, prospective, controlled s…”
BackgroundCancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
Magee, J. A., Piskounova, E., & Morrison, S. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.003 · Cited by 1,101
“Cancer Cell 2 These clinical observations appear to be explained by the persistence of rare imatinib-resistant CML stem cells (Chu et al., 2011; Graham et al., 2002; Holtz et al., 2002).”
BackgroundChronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
“In primitive stem/progenitor cells (CD34+38-) harvested from CML patients in durable complete cytogenetic response over 5 years, Bcr-Abl transcripts show no suggestion of a downward trend over time.(20) Furthermore, genomic PCR and PCR on individual LTC-IC colonies reveals that CML patients on imatinib who achieve com…”
BackgroundSelf-citationLi, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T. L., Chen, W., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.020 · Cited by 410
“Real-Time Q-PCR Analysis Q-PCR analysis performedwith primers and probes for p21,Bax, Puma,Noxa, Necdin, Gfi-1, and Sirt1, and BCR-ABL (B3A2) transcripts were measured using a real-time TaqMan assay as previously described (Chu et al., 2011).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R.
- Affiliations
- Division of Hematopoietic Stem Cell and Leukemia Research,
- City Of Hope National Medical Center (US)
- Department of Hematology and Hematopoietic Cell Transplantation, and
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-11-17
- Volume
- 118
- Issue
- 20
- Pages
- 5565-5572
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3217358
- OpenAlex
- W2062166095
- Cited by
- 245
- References
- 31
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 17 · 2020: 15 · 2019: 20 · 2018: 13 · 2017: 27 · 2016: 25 · 2015: 9 · 2014: 21 · 2013: 36 · 2012: 18
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA095684, R01 CA95684)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- chronic myeloid leukemia, leukemia stem cells, imatinib mesylate, BCR-ABL, CD34+CD38- cells, relapse after treatment discontinuation
- MeSH terms
- Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Bone Marrow, Humans, Neoplasm Transplantation, Piperazines, Pyrimidines, Remission Induction, Substance Withdrawal Syndrome, Time Factors, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Neoplasm, Residual, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. https://app.cochat.ai/papers/10.1182/blood-2010-12-327437
- The paper
- Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011). Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. https://doi.org/10.1182/blood-2010-12-327437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.